Babson Executive Education presents program for bio-pharma professionals Babson Executive Education offers Bio-Pharma: Mastering the business enterprise of Science, which can only help you contribute more to your business by strengthening your knowledge of strategy, finance, advertising, and leadership in the biotechnology and pharmaceutical sectors. Through this program, you shall identify your strategic part in your business, and develop the industry-relevant business acumen and improved managerial effectiveness you should address corporate challenges. As a specialist in the bio-pharma sector, you bring unique abilities to the table. Your understanding of the business enterprise of science is crucial to your organization’s long term – – and to your job.The submission of the AM461 IND follows closely on the heels of Amira’s lead DP2 antagonist, AM211, which is in Phase I human testing currently. Related StoriesFDA accepts Braeburn's resubmission of Probuphine NDA for reviewNovo Nordisk announces FDA acceptance of Tresiba for diabetes treatmentMylan sued in connection with ANDA filing for generic version of Zytiga Taking two DP2 applicants into clinical trials within four months of each other demonstrates our conviction to the prospective as well as the depth of our DP2 plan, said Peppi Prasit, Chief Scientific Officer. AM461 is normally structurally and metabolically unique from AM211. DP2 can be known as CRTH2 also, or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes.